Although further in vivo validation of these observations is required, our results indicate a possible strategy for the therapeutic use of MIF and TGF-β signaling inhibitors in patients with HIV-induced liver fibrosis. This evidence concerns the gene TGFB1 and Hepatic fibrosis.